title: Clinical evaluation of tissue plasminogen activator (t-PA) levels in patients with liver diseases.
abstract: Tissue plasminogen activator (t-PA) levels in plasma or serum were studied in 416 patients with liver diseases: acute hepatitis (AH, n = 30); fulminant hepatitis (FH, n = 36); chronic inactive hepatitis (CIH, n = 57); chronic active hepatitis (CAH, n = 39); compensated liver cirrhosis (cLC, n = 78); decompensated liver cirrhosis (dLC, n = 84); hepatocellular carcinoma (HCC, n = 64); advanced hepatocellular carcinoma (aHCC, n = 28); and compared with that of a control group (n = 106) of healthy subjects. The t-PA levels showed significant increase in patients with AH, FH, CAH, cLC, dLC and HCC, compared with normal controls. The abnormal rates in t-PA levels (higher than 8.3 ng/ml) for each type of liver diseases were 86.1% in FH, 46.2% in CAH, 50% in cLC, 85.7% in dLC, 67.2% in HCC, and 89.3% in aHCC. t-PA levels tended to be higher in more advanced liver diseases. t-PA levels significantly correlated positively with plasminogen activator inhibitor (PAI-1) in AH, cLC, dLC, HCC and aHCC, and negatively with plasmin alpha 1-plasmin inhibitor complex (PIC), plasminogen (Plg), FDP, AT III and alpha 2-plasmin inhibitor (alpha 2-PI) in dLC, prothrombin time (PT) and fibrinogen (Fbg) in HCC. t-PA levels in patients with FH, CAH and dLC were significantly higher than those in patients with AH, CIH and cLC, respectively. Moreover, the changes of t-PA levels in the clinical courses of various liver diseases revealed that t-PA levels increased sensitively with progression of liver diseases or in advanced liver diseases.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, St. Marianna University School of Medicine, Yokohama, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Okabe
authors.forename: I
authors.initials: I
authors.lastname: Kato
authors.forename: S
authors.initials: S
authors.lastname: Sato
authors.forename: T
authors.initials: T
authors.lastname: Kashiwabara
authors.forename: S
authors.initials: S
authors.lastname: Furuta
authors.forename: H
authors.initials: H
authors.lastname: Sato
authors.forename: K
authors.initials: K
authors.lastname: Tanikawa
authors.forename: R
authors.initials: R
authors.lastname: Kumashiro
authors.forename: M
authors.initials: M
authors.lastname: Kanayama
mesh_terms: D015415:Biomarkers / Q000097:blood; D006528:Carcinoma, Hepatocellular / Q000097:blood* / Q000453:epidemiology; D004797:Enzyme-Linked Immunosorbent Assay; D006505:Hepatitis / Q000097:blood* / Q000453:epidemiology; D006801:Humans; D008103:Liver Cirrhosis / Q000097:blood* / Q000453:epidemiology; D008111:Liver Function Tests; D008113:Liver Neoplasms / Q000097:blood* / Q000453:epidemiology; D015849:Plasminogen Inactivators / Q000097:blood; D011379:Prognosis; D010959:Tissue Plasminogen Activator / Q000097:blood*
chemical_list: D015415:Biomarkers; D015849:Plasminogen Inactivators; D010959:Tissue Plasminogen Activator